Reducing the Effects of Malaria in Children by Administering Repeated Preventive Doses

• Status: Completed
• Trial end date: 2007-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The general goal of the project is to assess the infectious status and immunity of mothers and children living in a malaria region. A major part of the study involves administering an effective antimalarial, sulfadoxine-pyrimethamine (Fansidar®), to children at the same timepoints as vaccinations, i.e. at age 3, 9 and 15 months. The main objective is to study safety, efficacy, and consequences of such a strategy in particular the ability to reduce the risk of anemia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Albert Schweitzer Hospital
• Collaborators: Bill and Melinda Gates Foundation; Bundesministerium fuer Bildung und Forschung (BMBF); Deutscher Akademischer Austausch Dienst; German Research Foundation; Medical Research Unit, Lambarene
• Treatments: Fanasil, pyrimethamine drug combination; Pyrimethamine; Sulfadoxine

Criteria

Inclusion Criteria:

• Informed consent

• Permanent residence in the study area

Exclusion Criteria:

• Allergy/hypersensitivity to sulfonamides or pyrimethamine

• Signs of severe hepatic or renal dysfunction not due to malaria